Objective-Adipose tissue inflammation and perturbation of adipokine secretion may contribute to the pathogenesis of cardiovascular diseases (CVD). Lipocalin-2 (LCN2), mainly released from adipocytes, has been shown to be positively associated with CVD in cross-sectional studies. We aimed to evaluate the association of LCN2 with CVD involving a population-based cohort recruited from the Shanghai Diabetes Study. Approach and Results-Serum LCN2 levels were measured using ELISA. Independent predictors of CVD development were identified using Cox proportion hazards regression. The predictive performances of the various models were assessed by Kaplan-Meier analysis. At baseline, circulating LCN2 was significantly associated with a cluster of traditional cardiovascular risk factors. Baseline LCN2 levels in male subjects who developed CVD events during follow-up were significantly higher than those who did not develop CVD events (P=0.012). However, such difference was not significant in female subjects. LCN2 was a predictor of CVD in men, which remained statistically significant after adjustment for traditional cardiovascular risk factors (hazard ratio, 1.038 [95% confidence interval, 1.017-1.060]). LCN2 remained significantly associated with incident CVD even after adjustment for renal function, adiponectin, and high-sensitivity C-reactive protein levels. Kaplan-Meier analysis suggested combination of LCN2 and high-sensitivity C-reactive protein might improve the prediction of CVD events in male subjects. Conclusions-Elevated circulating LCN2 level is an independent predictor of CVD events in men in a population-based cohort and adds to the prognostic value of high-sensitivity C-reactive protein, which is currently the most extensively studied biomarker of CVD. Measurement of serum LCN2 might be useful for early detection and intervention of CVD. (Arterioscler Thromb Vasc Biol. 2014;34:2457-2464.)
T he process of atherosclerosis may begin in youth and continue for decades, leading to both nonfatal and fatal cardiovascular events, including myocardial infarction, stroke, and sudden death. With primordial and primary prevention, cardiovascular disease (CVD) is largely preventable. 1 However, clinical practice of intervention of CVD at early stage was limited by the ability of established cardiovascular risk factors to identify specific individuals who are at higher risks of CVD. 2 Therefore, there is a need for additional markers of CVD. The adipokines, which are cytokines secreted by adipose tissue, are extensively studied due to the close association of obesity and CVD. The accumulation of excess lipid in adipose tissue is often accompanied by a chronic state of inflammation in which enlarged adipose tissue is infiltrated with inflammatory cells, resulting in augmented production of adipokines and thereby participates in the regulation of insulin sensitivity, lipid metabolism, and cardiovascular homeostasis. 3 The majority of the adipokines, including tumor necrosis factor-α, adipocyte fatty acid binding protein, interleukin-6, and resistin, possess proinflammatory properties. 3 Adiponectin, another important adipokine, have anti-inflammatory and protective cardiometabolic effects. 4 Lipocalin-2 (LCN2), also called neutrophil gelatinase-associated lipocalin and siderocalin, is mainly secreted by adipocytes. It belongs to the lipocalin family whose members generally bind a range of small hydrophobic molecules, specific cell-surface receptors and forms complexes with soluble macromolecules. 5 In previous animal study, LCN2-deficient mice showed significantly decreased fasting glucose, decreased insulin levels, and improved insulin sensitivity when challenged with aging, genetic, and dietary obesity. Inflammation and the accumulation of lipid peroxidation products were also significantly attenuated in the adipose tissues of LCN2-deficient mice. 6 Furthermore, LCN2-deficient mice were largely protected from high-fat diet-induced endothelial dysfunction and elevated systolic blood pressure (SBP). The protective function can be neutralized by administration of exogenous LCN2. 7 In line with these animal studies, LCN2 was found to be positively associated with metabolic syndrome and individual components, as well as markers for chronic inflammation in humans. 8, 9 The association between LCN2 and presence and severity of atherosclerosis was confirmed in cross-sectional study. 10 However, prospective studies addressing the cause-effect relationship between LCN2 and CVD are still lacking. In the present study, we investigated the development of CVD events in relation to the baseline LCN2 levels in a population-based cohort recruited from the Shanghai Diabetes Study.
Materials and Methods
Materials and method are available in the online-only Supplement.
Results

Characteristics of Subjects and Serum LCN2 Levels at Baseline
As outlined in Figure I in the online-only Data Supplement, of the 770 subjects with complete follow-up information and adequate baseline samples for analysis, 63 subjects were with CVD at baseline and 98 subjects developed CVD events after follow-up for a median duration of 74 months. The baseline characteristics of the study subjects are shown in Table 1 . The average age and body mass index (BMI) of the study subjects were 59.3 years and 24.0 kg/m 2 , respectively. The male subjects were older and included a larger proportion of patients with diabetes mellitus and hypertension compared with the female subjects. Moreover, the male subjects developed more CVD events during follow-up than the female subjects did (P=0.027). After adjusted for age, no significant difference was found in highsensitivity C-reactive protein (hsCRP) levels between male and female subjects. However, there were sex differences in serum LCN2 levels: men, median 17. Baseline characteristics of subjects according to different cardiovascular events status during follow-up are shown in Table 2 . In male subjects, those who developed CVD events during follow-up were older, had higher fasting plasma glucose, 2-hour postload plasma glucose, hemoglobin A1c (HbA1c), SBP, and lower estimated glomerular filtration rate (eGFR) than subjects did not develop CVD events (all P<0.05). In female subjects, those who developed CVD events during follow-up were older, had higher fasting plasma glucose, HbA1c, triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), SBP, diastolic blood pressure (DBP), and lower eGFR than subjects did not develop CVD events (all P<0.05). No matter in male or female subjects, the subjects who developed CVD events had higher baseline adiponectin and hsCRP levels compared with those who did not develop CVD events (all P<0.05). Notably, we found that circulating LCN2 levels in male subjects who developed CVD events during follow-up were significantly higher than subjects who did not develop CVD events (P=0.012). However, in female subjects the difference of baseline LCN2 levels between those who developed and did not develop CVD events was not significant (P=0.207).
Relationship Between Serum LCN2 Levels and Traditional Risk Factors
Pearson and partial correlation coefficients between LCN2 and metabolic, inflammatory, and other cardiovascular risk factors are presented in Table 3 . In the total cohort, serum LCN2 levels were significantly associated with age, BMI, waist circumference, fasting plasma glucose, 2-hour postload plasma glucose, homeostasis model assessment of insulin resistance, HbA1c, triglycerides, high-density lipoprotein cholesterol (HDL-C), SBP, DBP, eGFR, adiponectin, and hsCRP. For parameters other than fasting plasma glucose, 2-hour postload plasma glucose, and eGFR, these associations were not substantially altered after adjustment for age. As there were sex differences in LCN2 levels, we analyzed the association in male and female subjects. In men, LCN2 levels were associated with BMI, waist circumference, triglycerides, HDL-C, adiponectin, and hsCRP. In women, LCN2 levels were associated with BMI, waist circumference, homeostasis model assessment of insulin resistance, HbA1c, triglycerides, HDL-C, SBP, DBP, and hsCRP.
Baseline LCN2 Level Is an Independent Predictor of CVD Events in Male Subjects
The abilities of traditional risk factors and cytokines to predict future CVD events are evaluated with univariate Cox proportional hazard model and shown in cholesterol, SBP, and DBP), eGFR, adiponectin, hsCRP, and LCN2 (Table 5 ). There was no statistically significant interaction of LCN2 with sex on incident CVD (P=0.161). Baseline LCN2 was a predictor of CVD development in male subjects, which remained statistically significant after adjustment for traditional cardiovascular risk factors (HR, 1.038 [1.017-1.060]; model 1). However, the association between serum LCN2 and incident CVD in female subjects was not observed (P=0.576). In line with previous study, baseline hsCRP can predict future CVD events in male subjects and remained statistically significant after adjustment for traditional cardiovascular risk factors (HR, 1.199 [1.072-1.341]; model 2). As serum LCN2 level was correlated with renal function, eGFR was included into the analysis. 11 Baseline LCN2 level remained significant in predicting CVD development, but eGFR did not enter the model (model 3). When eGFR was replaced with serum adiponectin levels, the results were similar (model 4). When traditional cardiovascular risk factors, hsCRP, and LCN2 levels were included in the model, hsCRP (HR, 1.169 [1.039-1.315]) and LCN2 (HR, 1.035 [1.012-1.058]) both remained significant in predicting CVD development (model 5). These results suggested that LCN2 was a predictor of CVD events in male subjects, which remained significant after adjustment for traditional risk factors, renal function, adiponectin, and hsCRP levels.
Combination of LCN2 and hsCRP in Predicting Incident CVD Events in Male Subjects
The receiver-operating characteristic curves shown in Figure  II Data are mean±SD or median (interquartile range). P value for the difference between men and women. 2hPG indicates 2-hour postload plasma glucose; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LCN2, lipocalin-2; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; and TG, triglycerides. *P value adjusted for age; †log-transformed before analysis.
The event-free survival Kaplan-Meier curves for incident CVD stratified by the cutoff values of LCN2, hsCRP, as well as both LCN2 and hsCRP (all P<0.0001 by log-rank test) are shown in the Figure. The cutoff value for hsCRP (1.5 mg/L) was obtained from a previous study focusing on the distributions of hsCRP in middle-aged and older Chinese people. 12 The cutoff value for LCN2 (17.8 μg/L) was the median of the male subjects in this cohort. Either of the curves stratified by the cutoff values of LCN2 (Figure [A] ) or hsCRP (Figure [B] ) showed a clear separation during follow-up. Notably, subjects with both LCN2 and hsCRP levels above the cutoff points had significantly worse event-free survival than those with LCN2 and hsCRP levels below the cutoff points, respectively ( Figure  [C] and [D] ). These data demonstrated that the addition of LCN2 to hsCRP measurement might improve the prediction of CVD events in male subjects.
Discussion
In this cohort study of subjects without previous CVD, we demonstrated that baseline LCN2 levels were positively associated with the development of CVD in male subjects and similar association was not found in female subjects. LCN2 was a predictor of CVD events in men, which remained statistically significant after adjustment for traditional risk factors, renal function, adiponectin, and hsCRP levels. Combination of LCN2 and hsCRP might improve the prediction of CVD events. These results support our notion that circulating LCN2 level is linked to clinical cardiovascular outcomes. Elevated LCN2 levels have been found to be associated with several markers of CVD, such as intima-media thickness of arteries and the degree of severity. 10, 13 In addition to its circulating levels, plaque levels of LCN2 tended to be higher when intraplaque hemorrhage or luminal thrombus was present.
14 These findings were further supported by observational follow-up studies in which circulating LCN2 predicted the cardiovascular mortality in patients after cerebrovascular ischemia in a 4-year follow-up study. 15 The elevated LCN2 levels were associated with 2-year mortality in patients with chronic heart failure. 16 Whereas the above studies are supportive of a role of LCN2 in the pathogenesis of CVD, this is the first long-term study demonstrating that high LCN2 levels can predict CVD development in male subjects.
In line with previous cross-sectional study, 8, 9 we found that there were sex differences in serum LCN2 levels. Furthermore, baseline LCN2 level was an independent predictor of incident CVD events in men, but not in women. The results were consistent with our previous cross-sectional study, stating that significantly elevated serum LCN2 levels was found in male patients with coronary heart disease but not in women. 8 In a study of C56BL/6 mice on high-fat diets, it was also noted Data are mean±SD or median (interquartile range). P value for the difference between subjects developed CVD or did not develop CVD. 2hPG indicates 2-hour postload plasma glucose; BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LCN2, lipocalin-2; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; and TG, triglycerides.
*Log-transformed before analysis.
that LCN2 gene expression was markedly upregulated in male compared with female gonadal adipose tissue. 17 LCN2 had effect on estradiol biosynthesis and estrogen receptor signaling in female mice.
18 LCN2 deficiency mice had significantly reduced expression levels of aromatase, a key enzyme regulating estradiol biosynthesis in adipose tissue. 18 Female LCN2-deficient mice had reduced levels of serum 17 β-estradiol and downregulated expression of estrogen receptor α in adipose tissue after high-fat diet feeding or at old age. 18 These results suggested that LCN2 and levels of estrogens and their actions were interrelated. The sexual differences in LCN2 levels could be because of post-translational regulation and this potentially important question for unraveling the role of LCN2 in adipocyte biology also deserves further study. 17 The findings raise important clues on the pathophysiological mechanism underlying the association between LCN2 and CVD. Our results showed that baseline LCN2 was correlated with hsCRP, suggesting a role of LCN2 in chronic inflammation. LCN2 was previously shown to directly stimulate the expression and activity of 12-lipoxygenase as well as tumor necrosis factor-α production in fat tissues. 6 These results suggested that LCN2 contributed to chronic low-grade inflammatory status that was closely correlated with CVD development. In line with the proinflammatory function, earlier evidence also showed that the colocalization of LCN2 and matrix metallopeptidase 9, an important mediator of vascular remodeling and plaque instability, was found in atherosclerotic plaques in both animal and human studies. 14, 19 Hearts from LCN2-deficient mice showed improved functional recovery and reduced infarct size after reperfusion injury. 20 The above findings may partly account for the observed association between serum LCN2 and incident CVD in our study. Yet, LCN2 was reported to attenuate the early inflammatory response and impair bacterial clearance. High LCN2 levels in bronchoalveolar lavage were indicative of a detrimental outcome from pneumonia with Gram-positive bacteria. 21 However, it was reported that lack of LCN2 manifested a suppressed proinflammatory macrophage (M1) response and enhanced anti-inflammatory macrophage (M2) response. 22, 23 Further research is needed to clarify the potential pathophysiological mechanism of LCN2 in CVD development.
To date, the diagnostic approach of CVD is mainly based on risk factor evaluation, which has limitations in identifying the vulnerable patient at risk for CVD. This may be caused by the fact that the stage of these complex diseases cannot be captured by a single parameter or a set of markers and thus, clinicians have used additional tools to aid in clinical assessment of CVD. Recent studies demonstrated that several adipokines, including adiponectin and adipocyte fatty acid binding protein, could contribute to the multimarker strategy. [24] [25] [26] A U-shaped association was found between adiponectin and cardiovascular mortality, 27, 28 suggesting additional work is necessary to determine whether measurement of adiponectin could improve CVD risk prediction. In the latest researches, adipocyte fatty acid binding protein was found to predict cardiovascular morbidity and mortality, which remained significant after adjustment for traditional risk factors but not hsCRP levels. 25, 26 Based on our data, LCN2 predicted CVD development in men, which remained statistically significant after adjustment for traditional risk factors, adiponectin, and hsCRP. The cumulative survival 2hPG indicates 2-hour postload plasma glucose; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; and TG, triglycerides.
curves for incident CVD in men, stratified by the cutoff values of both LCN2 and hsCRP, showed a larger separation during follow-up than the curves stratified by the cutoff value of either marker. The above findings certified that combination of LCN2
and hsCRP might improve the prediction of CVD events and provide new strategy in clinical practice. Our current study has several limitations. Our cohort is Chinese, with lower BMI compared with Western cohorts. 2hPG indicates 2-hour postload plasma glucose; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; LCN2, lipocalin-2; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; and TG, triglycerides.
Results may not be generalizable to other groups of subjects. The cohort is small and the follow-up time is relatively short, leading to difficulty in analyzing the association of LCN2 and different types of CVD events. Besides, our analysis could only demonstrate the close correlation of LCN2 and incident CVD and further research is needed to clarify the potential pathophysiological mechanism of LCN2. Further studies in other populations focusing on both first and secondary CVD events are needed to support our conclusion. The clinical significance of LCN2 in predicting incident CVD events should be corroborated in larger long-term studies.
In summary, this study performed in the Chinese population revealed that elevated circulating LCN2 level is an independent predictor of CVD events in men and adds to the prognostic value of hsCRP. The results support the pathophysiological role of LCN2 in CVD and provided evidence related to LCN2 as a CVD marker. The clinical significance of LCN2 in predicting incident CVD events should be corroborated in larger long-term studies. 
